Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Conversion of shares

According to Husqvarna AB´s articles of association, owners of Class A shares have the right to have such shares converted to Class B shares. Conversion reduces the total number of votes in Husqvarna AB. When such a conversion has occurred, the company is obligated by the Act on Trading in Financial Instruments to disclose any such changeIn March 2023, at the request of shareholders, 360 Class A shares were converted to Class B shares. The total number of votes thereafter amounts to 156,729,587.9. The total number of registered shares in the company amounts to 576,343,778 shares of which

ALEXANDRIA PANKKIIRILIIKE OYJ: ACQUISITION OF OWN SHARES 28.04.2023

ALEXANDRIA PANKKIIRILIIKE OYJ NOTIFICATION    28.04.2023 at 18:30 EET   ALEXANDRIA PANKKIIRILIIKE OYJ: ACQUISITION OF OWN SHARES 28.04.2023   Date 28.04.2023  Exchange transaction Buy  Share class ALEX  Amount 200  Average price/share 6.7460 EURHighest price/share 6.7800 EURLowest price/share 6.6800 EURTotal price 1,349.20 EUR        The shares held by Alexandria Pankkiiriliike Oyj on 28.04.

Atria Plc: SHARE REPURCHASE 28.4.2023

Atria Plc  ANNOUNCEMENT  28.4.2023 Atria Plc: SHARE REPURCHASE 28.4.2023 In the Helsinki Stock Exchange Trade date           28.4.2023Bourse trade         BuyShare                  ATRAVAmount             2 000 SharesAverage price/ share    10,8000 EURTotal cost            21 600,00 EUR Atria Plc now holds a total of 50 002 sharesincluding the shares repurchased on 28.4.2023 On behalf of Atria Plc Nordea Bank Oyj Janne Sarvikivi           Sami

Wärtsilä Corporation: Share repurchase 28.4.2023

Wärtsilä Corporation Stock Exchange Release 28.4.2023 Wärtsilä Corporation: Share repurchase 28.4.2023 In the NASDAQ OMX Helsinki Trade date           28.4.2023Bourse trade         BuyShare                  WRT1VAmount             280 000 SharesAverage price/ share    10,4469 EURTotal cost            2 925 132,00 EUR Company now holds a total of 2 500 000 sharesincluding the shares repurchased on 28.4.2023 On behalf of

Golden Heights Aktiebolag (publ) delays the publication of the annual report for the financial year 2022

Golden Heights Aktiebolag (publ) (”Golden Heights”) delays the publication of the annual accounts for the financial year ended 31[st] December 2022. The estimated date for publication of the annual report for 2022 is 2 May 2023. The reason for the delay of the publication is longer periods of illness of key persons in the finance department. For more information, please visit www.iduna.se or contact:Madelene Wingård, Managing Director, madelene.wingard@iduna.se, tel: +46 340 59 54 10 The information comprises such as Golden Heights Aktiebolag (publ) is obliged to publicly disclose

Mandatory notification of trade

On April 28, the following transactions took place in Atea ASA (the Company): 1. Exercise of stock options Employees of the Atea group have exercised stock options. In total, 12,000 stock options were exercised under the original agreements. Atea will transfer 12,000 of its own shares to fulfill the Company's obligations under these employee stock option agreements. 2. Conversion of stock options and exercise of rights Employees of the Atea group have entered into an agreement with Atea to convert stock options into the right to receive shares in the Company of an equivalent

Bulletin from the 2023 Annual General Meeting in Samhällsbyggnadsbolaget i Norden AB (publ)

At the Annual General Meeting in Samhällsbyggnadsbolaget i Norden AB (publ) on 28 April 2023, the following items were resolved upon: Board of Directors Lennart Schuss, Ilija Batljan, Sven-Olof Johansson, Hans Runesten, Anne-Grete Strøm-Erichsen, Fredrik Svensson and Eva Swartz Grimaldi were re-elected as Members of the Board of Directors. Lars Rodert was elected as new Member of the Board of Directors. In addition, Lennart Schuss was re-elected as Chairman of the Board of Directors. Auditor The meeting re-appointed Ernst & Young AB as auditor with Jonas Svensson as auditor in

Annual General Meeting of HEXPOL AB

At today’s Annual General Meeting (AGM) of HEXPOL AB (publ), the following was resolved. Board of Directors, auditor and fees The number of directors will be seven. The meeting re-elected Alf Göransson, Jan‑Anders E. Månson, Malin Persson, Kerstin Lindell and Märta Schörling Andreen, and elected Nils-Johan Andersson and Henrik Elmin, as ordinary Board Members. Gun Nilsson has declined re-election. Alf Göransson was re-elected Chairman of the Board. The fees to the Board of Directors shall amount to a total of SEK 4,412,000 (including fees for committee work). The meeting re-elected

Aker Carbon Capture ASA: Initiation of share buyback program

Aker Carbon Capture ASA (the “Company”) has decided to initiate a buyback of up to 500.000 of its own shares for a total amount up to NOK 4 million. The buyback program may be carried out in the period from this announcement and until 8 May 2023. The purpose of the program is to fulfil the Company’s obligations under its employee share purchase program for 2023.The 2023 share purchase program allows the participants to acquire shares in the Company for a value of up to 25% of their gross annual salary. A price reduction of 25% of the share price will apply in exchange for the purchased

Integrum is granted patent approval for its OPRA™ Implant System in Australia

Mölndal, Sweden, April 27[th], 2023 - Integrum (publ) (Nasdaq First North Growth Market: INTEG B) announces today that the company has received a patent approval in Australia describing components and design features of the OPRA™ Implant System. The patent period extends until 2037.Integrum develops the OPRA™ Implant System, a revolutionary implant technology based on the company's deep expertise and innovations in osseointegration, that help amputees regain normal mobility and quality of life. The current patent includes claims covering the entire system, including the anchoring

Panoro Energy – Changes to the Board of Directors and Nomination Committee

Oslo, 28 April 2023 – Panoro Energy ASA (“Panoro” or the “Company”) announces today the following corporate changes in connection with the published calling notice for the Annual General Meeting (the “AGM”) to be held on May 23, 2023. As previously reported, Mrs. Hilde Ådland, who has served on the Board of Directors of Panoro (the “Board”) since 2016, has decided last year to retire from the Board at the next AGM. In making this decision, Mrs. Ådland cites other engagements, the need to rotate following a long tenure and to allow new perspectives to be brought to the Board. In

Panoro Energy – Notice of Annual General Meeting 2023

Oslo, 28 April 2023 – Panoro Energy ASA (“Panoro” or the “Company” with OSE Ticker: PEN) today announces that the 2023 Annual General Meeting (“AGM”) will be held virtually through the facilities of Euronext on 24 May 2023 at 10:00am CEST (Norwegian time). It will not be possible to attend in person. The formal notice of the AGM is attached to this release and can also be downloaded from Panoro’s website at www.panoroenergy.com. Important Information Shareholders and proxy holders who wish to participate at the AGM, must notify the Company of his/her presence five calendar days

Isofol initiates preclinical evaluation of arfolitixorin with Oncosyne AS

Gothenburg, Sweden, April 28, 2023 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the company has initiated a preclinical research collaboration with the Norwegian biotech company Oncosyne AS, to evaluate the effect of the drug candidate arfolitixorin in different doses combined with the cancer drug 5-FU, among others. This is an important step in the company´s previously communicated strategy to re-evaluate possible future tracks for arfolitixorin and to maximize the opportunities to take the drug candidate further toward potential market approval.The

K2A publishes updated base prospectus for MTN programme

K2A Knaust & Andersson Fastigheter AB (publ) (the "Company" or "K2A") established a non-secured so-called Medium Term Note programme with a total framework amount of SEK 3 billion or the equivalent amount in euro in May 2021, with terms that were subsequently amended in May 2022 (the "MTN programme"). In relation to the MTN programme, K2A drafted and published a base prospectus on 21 May 2021, which is subject to yearly updates. Thus, the Company has updated the base prospectus which has today on 28 April 2023 been approved and registered by the Swedish Financial Supervisory Authority (Sw.

EQL Pharma signs a license agreement with a large pharmaceutical company in Türkiye for Mellozzan (melatonin)

EQL has entered into an exclusive license agreement with a large pharmaceutical company for its product Mellozzan (melatonin) for Türkiye and Kazakhstan. "EQL has previously signed license agreements with parties for a number of countries, but this is a milestone as it is our first agreement with the sale of one of our products outside the borders of Europe," says Axel Schörling, CEO at EQL Pharma.Mellozzan contains the sleep hormone melatonin and is indicated for children who have ADHD and suffer from sleep difficulties, where so-called sleep hygiene measures have not helped. Mellozzan

Relesys A/S: Notification of transactions by persons discharging managerial responsibilities and persons closely associated with them

Relesys A/S | Managers' transactionsCompany Announcement No 5-2023Copenhagen, April 28. 2023Relesys A/S has received notification pursuant to article 19 of regulation (EU) no. 596/2014 of the below transactions related to shares in Relesys A/S made by persons discharging managerial responsibilities and/or persons closely related with them. Relesys board member Christian Lynge Hjorth has purchased a total of 450.000 shares from Relesys management team members. The shares were sold in bundles of 200.000 shares by Jesper Roesgaard, CEO & co-founder and 200.000 shares by Jens Ole Lebeck,

Report from Bravida Holding AB (publ)’s Annual General Meeting on 28 april 2023

At the Annual General Meeting in Bravida Holding AB (publ) today, the below resolutions were made in accordance with the board of directors’ and the nomination committee’s proposals.Adoption of income statements and balance sheets, allocation of the company’s result and discharge from liabilityThe Annual General Meeting adopted the income statement and the balance sheet as well as the consolidated income statement and the consolidated balance sheet in the annual report for the financial year 2022. The Annual General Meeting resolved on a dividend to the shareholders of SEK 3,25 per

SEM announces record date and payment date of the amendment fee for the written procedure under its outstanding bond loan

As announced by Swedish Electromagnet Invest AB (publ) (the “Company” or “SEM”) on 26 April 2023 in a press release (the “Press Release”), the written procedure (the “Written Procedure”) initiated on 13 April 2023 under the Company’s outstanding bond loan with ISIN SE0011167600 (the “Bonds”) was successfully concluded whereby, among other things, the maturity of the Bonds was extended until June 2026. SEM has undertaken in the Written Procedure to pay an amendment fee amounting to one (1.00) per cent. of the nominal amount of the Bonds as per the record date for the payment (being in an

Esmaeilzadeh Holding publishes annual report and sustainability report for 2022

“During the past year we have methodically continued executing our plans despite a turbulent business climate. The year began with strong confidence from the capital market in form of a bond loan of BSEK 1.2. The capital was used according to plan to invest in our portfolio companies, with the basic idea that discipline and resilience creates long-term value. The portfolio companies have grown and developed to new levels during the year, which is also reflected in our balance sheet. We are ready for an exciting 2023 and look forward with confidence to taking the next step in EHAB’s

Conversion of shares in AB Electrolux

According to AB Electrolux articles of association, owners of Series A shares are entitled to request that such shares are converted to Series B shares. Conversion reduces the total number of votes in the company.During April 2023, 180 Series A shares were at the request of shareholders converted to Series B shares, following which the total number of votes amounts to 35,680,690.5. The total number of registered shares in the company amounts to 283,077,393 shares, of which 8,192,168 are Series A shares and 274,885,225 are Series B shares.

Tourism Authority of Thailand takes a further step towards a sustainable destination

Amazing Thailand Roadshow to Oslo, Norway & Aarhus, Denmark 2023 was held as a further step to promote Thailand as one of sustainable destinations. Nearly 30 companies from travel agencies, charters and airlines from the Nordic and Baltic markets joined the Amazing Thailand Roadshow to meet 16 representatives from hotels and destination management companies with sustainable approach from Thailand. The events took place in Oslo, Norway on April 25 and in Aarhus, Denmark on April 27.     (Participants from travel agencies, charters, and airlines from the Nordic

Elicera Therapeutics receives conditional approval from the Medical Products Agency on its CAR T-cell Clinical Trial Application to test ELC-301 (CARMA-study)

Gothenburg, April 28, 2023 - Elicera Therapeutics AB (publ) (“Elicera”), a clinical stage cell and gene therapy company developing next-generation therapies based on oncolytic viruses and CAR T-cells armed with bystander immune activating properties using the company’s commercially available platform iTANK, today announced that it has received approval from the Swedish Medical Products Agency (MPA) on its Clinical Trial Application (CTA) to evaluate its CAR T-cell therapy, ELC-301, in treatment of patients with B-cell lymphoma (CARMA-study), conditional on certain further validations of its

There are no items matching the current filter
There are no more items matching the current filter
Back to top